Introduction
Alteration in the level of serum thyroid hormone profile has been described in several non-thyroidal systemic illnesses including acute heart diseases in otherwise euthyriod patients. This condition has been termed as "Euthyroid Sick Syndrome" and is characterized by decreased serum T3 and /or free T3, increased serum reverse T3 (rT3), plus normal serum TSH, T4, and free T4 levels 1 .Patients belonging to the STEMI group showed early elevations, in addition to higher mean reverse T3(rT3) and lower mean T3 and free T3 levels. 1 This syndrome has been reported to be found in severe chronic heart failure 2 , in acute myocardial infarction 3, 4 and as a rapidly emerging phenomenon during open-heart surgery. 5 Additionally hypothyroidism is emerging as a risk for coronary artery disease. 6 Evaluation of thyroid hormone plasma levels has been done in a number of studies in patients presenting with Acute Coronary Syndrome (ACS) and findings compared between Unstable Angina/Non-ST elevation MI (UA/NSTEMI) and ST Elevation acute MI (STEMI) groups. 1, 7 Some studies have reported association of greater hormonal changes with more severe cardiac events( STEMI and Death) and patients with complications. 1, 7, 8 An association of Euthyroid sick syndrome in ACS with poorer prognosis has been suggested in few studies. 1, 6 It has further been stated that the euthyroid sick syndrome has special significance in patients of ACS because low T3 levels in these patients signify severe disease and can be used as a marker for early invasive management in these patients. 6 Till date to my knowledge there are no data regarding thyroid profile in ACS patients from this part of world. This study aims to study the thyroid hormone profile in patients of ACS and to compare it in between STEMI and UA/NSTEMI groups.
Methods:
This is a hospital based, cross-sectional, comparative, observational study done from July 2015 to June 2017 in the department of cardiology of Manipal Teaching hospital, Nepal. 200 consecutive cases of acute coronary syndromes were taken for the study. Depending on the ECG findings and result of cardiac markers, the patients of ACS were categorized into following two groups as per American Heart Association (AHA) criteria. Group 1 considered cases showing ST depression / T wave inversion with normal or elevated cardiac markers. At the time of presentation, patients with UA and NSTEMI can be indistinguishable and therefore are considered together in these guidelines. 9 UA is defined as angina pectoris or equivalent ischemic discomfort with at least one of three features: (1) it occurs at rest (or with minimal exertion), usually lasting >10 minutes; (2) it is severe and of new onset (i.e., within the prior 4-6 weeks); and/or (3) it occurs with a crescendo pattern (i.e., distinctly more severe, prolonged, or frequent than previously). The diagnosis of NSTEMI is established if a patient with the clinical features of UA develops evidence of myocardial necrosis, as reflected in elevated cardiac biomarkers 10 and Group 2
Abstract
Background and aims: Serum thyroid hormonal changes can occur in acute or chronic non-thyroidal systemic illness including acute coronary syndrome in otherwise euthyroid individuals. In this study we aimed to assess thyroid hormonal profile in patients presenting with acute coronary syndromes (ACS) and compare between ST segment elevated myocardial infarction and unstable angina/Non ST segment elevated myocardial infarction.
Methods: A hospital based, retrospective, observational comparative study was designed. Data of all patients with acute coronary syndrome presenting to hospital were collected from July 2015 through June 2017 in a pre-structured proforma and analyzed. 12 Known patients of thyroid disorders on treatment, patients suffering from other diseases such as neoplasia, chronic renal failure, chronic obstructive lung diseases, cirrhosis of liver and active infective conditions and patients taking Amiodarone, Lithium, Steroids or those who received iodinated contrast agent within the previous 2 weeks were excluded. Data were collected in a preformed proforma and analyzed in SPSS software version 16. The significant difference between two groups was compared using ANOVA. Pearson's correlation coefficient, Chi-square test, t-tests, etc was used to find group association. Odds ratio was calculated for required appropriate values and p values were considered significant at a predetermined level of < 0.05.
Results:
Two hundred ACS patients between 23 years to 88 years with mean age of 61.33 ± 12.30 years were studied. 115 (57.5%) were more than 60 years, 70 (35%) were 40-60 years and 15 (7.5%) belonged to age group of 20-40 years. 127 (63.5%) were males. 116 (58%) were STEMI patients while 84 (42%) were UA/ NSTEMI patients. 76 (39%) patients were hypertensive and on medications while only 21 (10.5%) were diabetics. 134 (67%) patients were smokers. Thyroid hormone analysis was done in all the ACS patients and was found abnormal in 47 (23.5%) of the patients. Out of 127 males and 73 females with ACS, 27 (21.25%) patients had abnormal TFTs while 20 (27.39%) female patients with ACS had abnormal TFTs. There was no statistically significant difference in prevalence of abnormal thyroid hormone profile in males and females with ACS (p=0.35).
Of the 47 patients with abnormal thyroid hormone profile, 28(59.5%) had Euthyroid Sick Syndrome, 12(25.5%) had subclinical hypothyroidism, 5(10.6%) had subclinical hyperthyroidism and 2(4.25%) had low fT4 with normal fT3 and normal TSH. Table 1 further divides the findings in subcategories of STEMI and UA/NSTEMI. Further analysis in mean average hospital stay and mortality with abnormal thyroid hormone profiles in these patients was analyzed. The mean hospital stay was significantly higher (p=<0.001) in both the groups (Table 4) . Mortality was slightly higher in patients having abnormal TFT reports but not significant in both the groups (p= 0.164 and 0.1429 respectively) (table 5). 
